DDF

Incorporated in 2015 as the first and leading dementia focused VC, the first Dementia Discovery Fund (DDF-1) saw its final close at £250 million in 2018 making it the world's largest venture capital fund focused on discovering and developing novel disease-modifying therapeutics for all forms of dementia. Seven leading pharmaceutical companies - Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and Takeda - along with AARP, Aegon, Bill Gates, British Patient Capital, NFL Players Association, Quest Diagnostics, UnitedHealth Group, the UK's Department of Health and Social Care, and the charity Alzheimer's Research UK (among others) have invested in the Fund... Advised by SV Health Investors (SV), a leading life sciences venture capital and growth equity firm, the investment and strategic support DDF can provide is unrivalled. SV has been investing in biotech companies for over 30 years and brings a proven track record of identifying early-stage research..

Registration numbers: 409119 (W), OC 308829 (W)

VAT numbers: 227 0451 34

Primary location: Boston United States